/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Morphic Holding, Inc. ("Morphic" or the "Company") (NASDAQ: MORF). Such...
/PRNewswire/ -- The law firm of Robbins Geller Rudman & Dowd LLP is investigating potential violations of U.S. federal securities laws involving Morphic...
/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Morphic Holding, Inc. ("Morphic" or the "Company") (NASDAQ: MORF). Such...
Stocks that traded heavily or had substantial price changes on Wednesday: MillerKnoll, Peloton rise; Progress Software, NextEra Energy fall
What you need to know… The S&P 500 Index ($SPX ) (SPY ) on Monday closed up +0.40%, the Dow Jones Industrials Index ($DOWI ) (DIA ) closed up +0.13%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed up...
The S&P 500 Index ($SPX ) (SPY ) today is up +0.23%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is down -0.02%, and the Nasdaq ($IUXX ) (QQQ ) is up +0.26%. Stocks are mixed, with the S&P 500 earlier...
Morning Markets December E-Mini S&P 500 futures (ESZ2 3) are down -0.32%, and the Dec Nasdaq 100 E-Mini futures (NQZ2 3) are down -0.33%. Stock index futures this morning are mildly lower, following losses...
The trio all have late-stage therapies with blockbuster potential.
Continued enrollment of EMERALD-1 phase 2a trial of MORF-057 in patients with ulcerative colitis Announced key appointments and advancements in leadership...
WALTHAM, Mass., June 09, 2022 (GLOBE NEWSWIRE) -- Morphic Therapeutic (Nasdaq: MORF), a biopharmaceutical company developing a new generation of oral...